Clincosm LogoSign in Get a demo

The Neurofibromatosis-associated Tumor Biobank

Sponsor
Ren tingting (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03359304
Collaborator
(none)
300
Enrollment
120
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material.

    Questionnaire information, including health history, growth and development, physical activity and family medical history information.

    If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Family-Based
    Time Perspective:
    Prospective
    Official Title:
    Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction
    Anticipated Study Start Date :
    Mar 1, 2018
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Mar 1, 2028

    Outcome Measures

    Primary Outcome Measures

    1. Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor [3 years]

      To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor

    Exclusion Criteria:

    non-asian

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Ren tingting

    Investigators

    • Principal Investigator: Tingting Ren, phD, Peking University People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ren tingting, Musculoskeletal Tumor Center, Peking University People's Hospital
    ClinicalTrials.gov Identifier:
    NCT03359304
    Other Study ID Numbers:
    • PKU-MPNST
    First Posted:
    Dec 2, 2017
    Last Update Posted:
    Dec 2, 2017
    Last Verified:
    Nov 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ren tingting, Musculoskeletal Tumor Center, Peking University People's Hospital
    bone tumor
    Additional relevant MeSH terms:
    Neurofibromatoses
    Neurofibromatosis 1
    Neurofibroma

    Study Results

    No Results Posted as of Dec 2, 2017